AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 3 cutMore cutting
Key stats
Fundamentals Sep 30- Open
- $102.18
- 52-wk high
- $152.14
- High
- $102.80
- 52-wk low
- $100.17
- Low
- $100.90
- Prev close
- $102.63
- Mkt cap
- $23.57B
- P/E
- 24.0x
- Volume
- 2.03M
- Fwd P/E
- 17.4x
- Beta
- 1.00
- Div yield
- 1.65%
- P/S
- 2.6x
- P/B
- 2.4x
- Profit margin
- +11.2%
- Op margin
- +17.0%
- ROE
- +9.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about XYL filings
Are insiders buying or selling Xylem Inc (XYL) stock?
Neither. Xylem Inc (XYL) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded XYL recently?
None. No member of Congress disclosed a XYL trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this XYL smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders are trading both ways.
What funds are doing
Buys/Adds (1)
- AQ
AQR
$116.0M
added
Sells/Trims (2)
- QR
Qube Research
$36.9M
sold
- P7
Point72
$34.3M
sold
What insiders are doing
Buys (1)
- PJ
Peribere Jerome A
$141K
bought
Sells (1)
- MG
Mcshane Geri-Michelle
$501K
sold
How top traders are positioned
No tracked top-trader positions in XYL right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 9.0% above what analysts expected.
Earnings per share
$1.34 expected
Revenue
No comparable estimate
FY2026 guidance
$9.20B
No comparable estimate
Reports Oct 27, 2026, in 26 days
Estimates as of Sep 30, 2026
EPS expected
$1.41 to $1.53
Revenue expected
17 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.27B | $2.40B | $2.13B | $2.34B |
| Cost of what it sold | $1.39B | $1.47B | $1.32B | $1.37B |
| Gross profit | $883.0M | $932.0M | $803.0M | $963.0M |
| What it spent | ||||
| Research and development | $52.0M | $60.0M | $56.0M | $59.0M |
| Sales and admin | $474.0M | $486.0M | $472.0M | $503.0M |
| Other operating costs | $23.0M | $33.0M | $31.0M | $11.0M |
| Total operating expenses | $549.0M | $579.0M | $559.0M | $573.0M |
| What was left | ||||
| Operating profit | $334.0M | $353.0M | $244.0M | $390.0M |
| Interest on debt | $6.0M | $6.0M | $4.0M | $7.0M |
| Profit before tax | $297.0M | $368.0M | $244.0M | $364.0M |
| Tax | $71.0M | $35.0M | $55.0M | $103.0M |
| Net profit | $227.0M | $335.0M | $185.0M | $263.0M |
| EBITDA | $444.0M | $517.0M | $388.0M | $511.0M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace